The FDA has approved two cell-based gene therapies for sickle cell disease, Casgevy from CRISPR/Vertex and Lyfgenia from Bluebird Bio, which are the first treatments available to individuals with SCD in the United States.
For more than 57 years, The Atlanta Voice has fought for the well-being of Atlanta’s African American community. Please support our work.
The Atlanta Voice is the leading news source dedicated to the well-being of Atlanta’s African American community.
The FDA has approved two cell-based gene therapies for sickle cell disease, Casgevy from CRISPR/Vertex and Lyfgenia from Bluebird Bio, which are the first treatments available to individuals with SCD in the United States.
